Surpassing $1 billion in annual sales marks a major milestone for any biopharmaceutical company, and Acadia Pharmaceuticals (ACAD) is steadily moving toward that goal. Driven by continued commercial growth across its key products and expanding market opportunities, the company is positioning itself for its next phase of long-term success.
Acadia is focused on developing drugs for underserved neurological and rare disease communities around the world. Its commercial portfolio includes Nuplazid, the first and only FDA-approved therapy for Parkinson's disease psychosis, and Daybue, the first approved treatment for Rett syndrome.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com